Understanding the molecular events which underlie megakaryocyte (MK) formation has lagged behind that of erythroid and myeloid cell development. With the recent cloning of thrombopoietin (TPO), and demonstration of its critical role in MK and platelet production, we have the opportunity to gain fundamental new insights into this intriguing process. The long term goal of this research proposal is to identify the molecular mechanisms responsible for MK proliferation and differentiation. To this end we propose a research plan of three specific aims. First, we will study the structural features of TPO responsible for its biological activity. In addition to our previous methods used to study GM-CSF, IL-3 and SCF, we will employ a novel """"""""back mutant"""""""" screening procedure to rapidly detect sites on the molecule critical for receptor interaction. Second, we will generate and screen two cDNA libraries in an attempt to identify genes responsible for developmental progression of MK progenitor cells. Here, too, we will employ newly developed methods to purify MK and their progenitors, and then to screen sense and antisense libraries by both gain- of-function and loss-of-function strategies. Finally, studies of the third specific aim will investigate the genetic basis for polyploidy, the most remarkable and least understood feature of hematopoietic development. The availability of purified cell cycle-synchronized normal marrow MK will allow us to investigate several hypotheses of the physiologic basis for polyploidy, the uncoupling of DNA synthesis and mitosis. A better understanding of the molecular basis for these three processes, growth factor binding to receptor, the genetic mechanism(s) of lineage development, and the biochemical basis of polyploidy will advance our understanding of normal thrombopoiesis, and has important implications for both the therapeutic use of TPO and for the normal physiology of cell division and differentiation.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project (R01)
Project #
Application #
Study Section
Hematology Subcommittee 2 (HEM)
Program Officer
Mufson, R Allan
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Washington
Internal Medicine/Medicine
Schools of Medicine
United States
Zip Code
Hitchcock, Ian S; Chen, Maximus M; King, Jennifer R et al. (2008) YRRL motifs in the cytoplasmic domain of the thrombopoietin receptor regulate receptor internalization and degradation. Blood 112:2222-31
Barroga, Charlene F; Pham, Hang; Kaushansky, Kenneth (2008) Thrombopoietin regulates c-Myb expression by modulating micro RNA 150 expression. Exp Hematol 36:1585-92
Yoshida, Kozue; Kirito, Keita; Yongzhen, Hu et al. (2008) Thrombopoietin (TPO) regulates HIF-1alpha levels through generation of mitochondrial reactive oxygen species. Int J Hematol 88:43-51
Nakao, Takafumi; Geddis, Amy E; Fox, Norma E et al. (2008) PI3K/Akt/FOXO3a pathway contributes to thrombopoietin-induced proliferation of primary megakaryocytes in vitro and in vivo via modulation of p27(Kip1). Cell Cycle 7:257-66
Kaushansky, Kenneth (2008) Historical review: megakaryopoiesis and thrombopoiesis. Blood 111:981-6
McIntosh, Bryan; Kaushansky, Kenneth (2008) Transcriptional regulation of bone marrow thrombopoietin by platelet proteins. Exp Hematol 36:799-806
Chanprasert, Supantitra; Geddis, Amy E; Barroga, Charlene et al. (2006) Thrombopoietin (TPO) induces c-myc expression through a PI3K- and MAPK-dependent pathway that is not mediated by Akt, PKCzeta or mTOR in TPO-dependent cell lines and primary megakaryocytes. Cell Signal 18:1212-8
Kaushansky, Kenneth (2006) Hematopoietic growth factors, signaling and the chronic myeloproliferative disorders. Cytokine Growth Factor Rev 17:423-30
Geddis, Amy E; Fox, Norma E; Kaushansky, Kenneth (2006) The Mpl receptor expressed on endothelial cells does not contribute significantly to the regulation of circulating thrombopoietin levels. Exp Hematol 34:82-6
Coleman, Thomas R; Westenfelder, Christof; Togel, Florian E et al. (2006) Cytoprotective doses of erythropoietin or carbamylated erythropoietin have markedly different procoagulant and vasoactive activities. Proc Natl Acad Sci U S A 103:5965-70

Showing the most recent 10 out of 93 publications